Literature DB >> 16047135

[Current concepts in diagnosis and treatment of tachyarrhythmias].

J O Schwab1, B Lüderitz.   

Abstract

A diagnostic and therapeutic approach of supraventricular and ventricular tachyarrhythmia is always challenging. Several criteria serve to discriminate correctly between these two types of tachycardia. Cardiac arrhythmias are terminated reliably by intravenous (IV) application of antiarrhythmic drugs: adenosine for supraventricular arrhythmia, amiodarone or ajmaline for ventricular tachycardia. Furthermore, AV-nodal tachycardia, atrioventricular reciprocating tachycardia, and typical atrial flutter is treated curatively by radiofrequency ablation during an electrophysiological study. This interventional therapy is well established in patients suffering from ventricular premature contractions or tachycardia originating in the right or left ventricular outflow tract. Aside treatment with an implantable defibrillator, patients with coronary artery disease highly benefit from adjusted pharmaceutical treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047135     DOI: 10.1007/s00108-005-1469-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

Review 1.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society.

Authors:  Carina Blomström-Lundqvist; Melvin M Scheinman; Etienne M Aliot; Joseph S Alpert; Hugh Calkins; A John Camm; W Barton Campbell; David E Haines; Karl H Kuck; Bruce B Lerman; D Douglas Miller; Charlie Willard Shaeffer; William G Stevenson; Gordon F Tomaselli; Elliott M Antman; Sidney C Smith; Joseph S Alpert; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs; Richard O Russell; Silvia G Priori; Jean Jacques Blanc; Andzrej Budaj; Enrique Fernandez Burgos; Martin Cowie; Jaap Willem Deckers; Maria Angeles Alonso Garcia; Werner W Klein; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Carlos Araujo Morais; Ali Oto; Otto Smiseth; Hans Joachim Trappe
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

Review 2.  [Atrial fibrillation -- interventional therapy with respect to age].

Authors:  Th Lewalter; B Lüderitz
Journal:  Dtsch Med Wochenschr       Date:  2005-03-24       Impact factor: 0.628

3.  Results and significance of Holter monitoring after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction.

Authors:  J O Schwab; H Schmitt; M Coch; F Bernhoeft; W Waas; T Raedle-Hurst; H H Tillmanns; B Waldecker
Journal:  Am J Cardiol       Date:  2001-02-15       Impact factor: 2.778

4.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

5.  Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.

Authors:  A E Epstein; J T Bigger; D G Wyse; D W Romhilt; R A Reynolds-Haertle; A P Hallstrom
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

6.  Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome.

Authors:  Carlo Pappone; Francesco Manguso; Raffaele Santinelli; Gabriele Vicedomini; Simone Sala; Gabriele Paglino; Patrizio Mazzone; Christopher C Lang; Simone Gulletta; Giuseppe Augello; Ornella Santinelli; Vincenzo Santinelli
Journal:  N Engl J Med       Date:  2004-09-16       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.